Absolute bioavailability, mass balance, elimination route, and metabolite profile of the selective oral MEK1/2 inhibitor pimasertib in cancer patients.

e13552 Background: The MAPK signaling pathway is aberrantly upregulated in cancer. Pimasertib is a selective, uncompetitive MEK1/2 inhibitor with potent activity in human melanoma cells and xenogra...